Actively Recruiting
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
Led by M.D. Anderson Cancer Center · Updated on 2025-11-06
105
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking letermovir every day without interruption.
CONDITIONS
Official Title
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Allogeneic hematopoietic cell transplant recipients with positive CMV serostatus
- Receiving letermovir prophylaxis around day 90 post transplant (+/- 7 days)
- At high risk for CMV reactivation after day 100, including any of the following:
- Prior or active graft versus host disease requiring systemic steroids
- Mismatch stem cell donor (haploidentical, mismatch unrelated donor, match related donor with one mismatch at HLA-A, HLA-B, or HLA-DR, or cord donor recipients)
- Received T cell depletion or anti-thymoglobulin during conditioning
- CMV reactivation prior to day 100 post transplant
- Use of steroids at any dose within 2 weeks of enrollment
You will not qualify if you...
- Under 18 years of age
- Discharged from the institution and unwilling to return for follow-up
- Actively undergoing treatment for clinically significant CMV infection at screening
- Allergic or intolerant to letermovir or with history of letermovir-resistant CMV infection
- Unable to obtain letermovir for extended prophylaxis beyond day 100
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
F
Fareed Khawaja, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here